News
PROTERIS BIOTECH AWARDED NEW FEDERAL GRANT TO DEVELOP A BIOLOGIC EYE DROP FOR THE TREATMENT OF DRY EYE
The National Eye Institute of the National Institutes of Health (NIH) has awarded Small Business Innovation Research (SBIR) grant R43-EY037590 to Proteris Biotech, Inc. (PB) to continue preclinical development of an innovative eye drop technology for the treatment of dry eye. The ultimate goal is a new U.S. Food and Drug Administration (FDA)-approved biologic drug.
Read the releaseProteris Biotech awarded second federal grant to develop a biologic eye drop for the treatment of epitheliopathy in dry eye
The National Eye Institute of the National Institutes of Health (NIH) has awarded Small Business Technology Transfer (STTR) grant R41-EY034396 to Proteris Biotech, Inc. (PB) to continue development of an innovative eye drop technology for the treatment of ocular surface damage in dry eye, also called epitheliopathy. The ultimate goal is a new U.S. Food and Drug Administration (FDA)-approved biologic drug. The grant begins September 30, 2023.
Read the releaseProteris Biotech awarded federal grant to develop Protearin for dry eye
The National Eye Institute of the National Institutes of Health (NIH) has awarded a Small Business Technology Transfer (STTR) grant R41-EY025890 to Proteris Biotech, Inc. (PB) to develop innovative technology for the treatment of dry eye. The ultimate goal is a new U.S. Food and Drug Administration (FDA) approved biotherapeutic called Protearin. The grant will begin May 1, 2016.
Read the release (PDF)Promising USC study focuses on treatment for dry eyes
A natural protein in tears could help researchers looking at the common affliction.
Read the articleSC CTSI-Supported Researchers make important discovery on Ameliorate Dry Eye treatment
Researchers find natural protein seals ocular surface and offers promise to ameliorate dry eye.
Read the article